Nishino Michiya, Krane Jeffrey F
Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Department of Pathology, Harvard Medical School and Brigham and Women's Hospital, 75 Francis Street, Amory 3, Boston, MA 02115, USA.
Surg Pathol Clin. 2018 Sep;11(3):467-487. doi: 10.1016/j.path.2018.05.002.
Genomic, clinical, and pathologic studies have prompted a more risk-stratified approach to the management of patients with thyroid nodules. The recent nomenclature change concerning noninvasive follicular thyroid neoplasm with papillary-like nuclear features reflects the clinical trend toward conservative treatment choices for carefully selected low-risk thyroid neoplasms. These developments have occurred in parallel with a growing array of molecular tests intended to improve clinical triage for patients with indeterminate fine needle aspiration diagnoses. This review discusses the implications of the nomenclature revision on the interpretation of thyroid fine needle aspiration and updates available ancillary molecular tests for thyroid fine needle aspirations.
基因组学、临床和病理学研究促使人们对甲状腺结节患者的管理采取更具风险分层的方法。最近关于具有乳头状核特征的非侵袭性滤泡性甲状腺肿瘤的命名变化反映了临床趋势，即对于精心挑选的低风险甲状腺肿瘤采取保守治疗选择。这些进展与越来越多旨在改善对细针穿刺诊断不确定患者的临床分类的分子检测同时出现。本文综述讨论了命名修订对甲状腺细针穿刺解读的影响，并更新了甲状腺细针穿刺可用的辅助分子检测方法。
